Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 13/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961314 | 0.97 | BCHE (0.47) | USP2HSD17B10POLBBCHENPC1 | |
| SCHEMBL3959652 | 0.81 | BCHE (0.49) | USP2HSD17B10BCHELPAR1LPAR2 | |
| SCHEMBL3960798 | 0.81 | TRPM8 (0.49) | USP2HSD17B10BCHENPC1LPAR1 | |
| SCHEMBL3960100 | 0.80 | PPARA (0.49) | USP2HSD17B10POLB | |
| SCHEMBL3964009 | 0.79 | TRPM8 (0.47) | USP2HSD17B10 | |
| SCHEMBL3963241 | 0.78 | PPARA (0.46) | USP2HSD17B10 | |
| SCHEMBL3964923 | 0.78 | PPARA (0.46) | USP2HSD17B10 | |
| SCHEMBL3965294 | 0.78 | PPARA (0.46) | USP2HSD17B10 | |
| SCHEMBL3960463 | 0.78 | PPARD (0.44) | USP2HSD17B10 | |
| SCHEMBL3967928 | 0.77 | POLB (0.45) | USP2HSD17B10POLBBCHENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | GPR119, PPARA, PPARG | USP2 3611/4885HSD17B10 187/4885POLB 2597/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | USP2 4267/4885HSD17B10 193/4885POLB 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.